Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer.

Muntasell A, Servitja S, Cabo M, Bermejo B, Pérez-Buira S, Rojo F, Costa-García M, Arpí O, Moraru M, Serrano L, Tusquets I, Martínez MT, Heredia G, Vera A, Martínez-García M, Soria L, Comerma L, Santana-Hernández S, Eroles P, Rovira A, Vilches C, Lluch A, Albanell J, López-Botet M.

Cancer Immunol Res. 2019 Aug;7(8):1280-1292. doi: 10.1158/2326-6066.CIR-18-0896. Epub 2019 Jun 12.

PMID:
31189644
2.

Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study.

Pineda-Moncusí M, Servitja S, Tusquets I, Diez-Perez A, Rial A, Cos ML, Campodarve I, Rodriguez-Morera J, Garcia-Giralt N, Nogués X.

Breast Cancer Res Treat. 2019 Aug;177(1):53-60. doi: 10.1007/s10549-019-05289-7. Epub 2019 May 24.

PMID:
31127467
3.

Changes in dietary intake, plasma carotenoids and erythrocyte membrane fatty acids in breast cancer survivors after a lifestyle intervention: results from a single-arm trial.

Buckland G, Travier N, Arribas L, Del Barco S, Pernas S, Zamora E, Bellet M, Cirauqui B, Margelí M, Muñoz M, Tusquets I, Arcusa A, Javierre C, Moreno F, Valverde Y, Jansen E, Chajès V, Castro C, Agudo A.

J Hum Nutr Diet. 2019 Aug;32(4):468-479. doi: 10.1111/jhn.12621. Epub 2019 Jan 21.

PMID:
30663156
4.

Alkylphenolic compounds and risk of breast and prostate cancer in the MCC-Spain study.

Peremiquel-Trillas P, Benavente Y, Martín-Bustamante M, Casabonne D, Pérez-Gómez B, Gómez-Acebo I, Oliete-Canela A, Diéguez-Rodríguez M, Tusquets I, Amiano P, Mengual L, Ardanaz E, Capelo R, Molina de la Torre AJ, Salas Trejo D, Fernández-Tardón G, Lope V, Jimenez-Moleon JJ, Marcos-Gragera R, Dierssen-Sotos T, Azpiri M, Muñoz M, Guevara M, Fernández-Villa T, Molina-Barceló A, Aragonés N, Pollán M, Castaño-Vinyals G, Alguacil J, Kogevinas M, de Sanjosé S, Costas L.

Environ Int. 2019 Jan;122:389-399. doi: 10.1016/j.envint.2018.12.007. Epub 2018 Dec 13.

5.

Vitamin D levels in Mediterranean breast cancer patients compared with those in healthy women.

Pineda-Moncusí M, Garcia-Perez MA, Rial A, Casamayor G, Cos ML, Servitja S, Tusquets I, Diez-Perez A, Cano A, Garcia-Giralt N, Nogues X.

Maturitas. 2018 Oct;116:83-88. doi: 10.1016/j.maturitas.2018.07.015. Epub 2018 Jul 29.

PMID:
30244785
6.

Bone health evaluation one year after aromatase inhibitors completion.

Pineda-Moncusí M, Servitja S, Casamayor G, Cos ML, Rial A, Rodriguez-Morera J, Tusquets I, Diez-Perez A, Garcia-Giralt N, Nogués X.

Bone. 2018 Dec;117:54-59. doi: 10.1016/j.bone.2018.09.010. Epub 2018 Sep 14.

PMID:
30223134
7.

Changes in metabolic risk, insulin resistance, leptin and adiponectin following a lifestyle intervention in overweight and obese breast cancer survivors.

Travier N, Buckland G, Vendrell JJ, Fernandez-Veledo S, Peiró I, Del Barco S, Pernas S, Zamora E, Bellet M, Margeli M, Cirauqui B, Muñoz M, Tusquets I, Arcusa A, Javierre C, Moreno F, Rodriguez A, Agudo A.

Eur J Cancer Care (Engl). 2018 Jul;27(4):e12861. doi: 10.1111/ecc.12861. Epub 2018 Jun 5.

PMID:
29869823
8.

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations.

Tamborero D, Rubio-Perez C, Deu-Pons J, Schroeder MP, Vivancos A, Rovira A, Tusquets I, Albanell J, Rodon J, Tabernero J, de Torres C, Dienstmann R, Gonzalez-Perez A, Lopez-Bigas N.

Genome Med. 2018 Mar 28;10(1):25. doi: 10.1186/s13073-018-0531-8.

9.

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial.

Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chacon JI, Chan A, Morales S, Alvarez I, Plazaola A, Zambetti M, Redfern AD, Dittrich C, Dent RA, Magazzù D, De Fato R, Valagussa P, Tusquets I.

JAMA Oncol. 2018 Mar 1;4(3):302-308. doi: 10.1001/jamaoncol.2017.4612.

10.

Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy.

Muntasell A, Cabo M, Servitja S, Tusquets I, Martínez-García M, Rovira A, Rojo F, Albanell J, López-Botet M.

Front Immunol. 2017 Nov 13;8:1544. doi: 10.3389/fimmu.2017.01544. eCollection 2017. Review.

11.

Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer.

Sabbaghi M, Gil-Gómez G, Guardia C, Servitja S, Arpí O, García-Alonso S, Menendez S, Arumi-Uria M, Serrano L, Salido M, Muntasell A, Martínez-García M, Zazo S, Chamizo C, González-Alonso P, Madoz-Gúrpide J, Eroles P, Arribas J, Tusquets I, Lluch A, Pandiella A, Rojo F, Rovira A, Albanell J.

Clin Cancer Res. 2017 Nov 15;23(22):7006-7019. doi: 10.1158/1078-0432.CCR-17-0696. Epub 2017 Aug 18.

12.

The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population: The MCC-Spain Study.

Gómez-Acebo I, Dierssen-Sotos T, Palazuelos C, Pérez-Gómez B, Lope V, Tusquets I, Alonso MH, Moreno V, Amiano P, Molina de la Torre AJ, Barricarte A, Tardon A, Camacho A, Peiro-Perez R, Marcos-Gragera R, Muñoz M, Michelena-Echeveste MJ, Ortega Valin L, Guevara M, Castaño-Vinyals G, Aragonés N, Kogevinas M, Pollán M, Llorca J.

PLoS One. 2016 Aug 10;11(8):e0159672. doi: 10.1371/journal.pone.0159672. eCollection 2016.

13.

Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma.

Rojo F, González-Pérez A, Furriol J, Nicolau MJ, Ferrer J, Burgués O, Sabbaghi M, González-Navarrete I, Cristobal I, Serrano L, Zazo S, Madoz J, Servitja S, Tusquets I, Albanell J, Lluch A, Rovira A, Eroles P.

Br J Cancer. 2016 Jul 26;115(3):322-31. doi: 10.1038/bjc.2016.204. Epub 2016 Jul 12.

14.

Total Effective Xenoestrogen Burden in Serum Samples and Risk for Breast Cancer in a Population-Based Multicase-Control Study in Spain.

Pastor-Barriuso R, Fernández MF, Castaño-Vinyals G, Whelan D, Pérez-Gómez B, Llorca J, Villanueva CM, Guevara M, Molina-Molina JM, Artacho-Cordón F, Barriuso-Lapresa L, Tusquets I, Dierssen-Sotos T, Aragonés N, Olea N, Kogevinas M, Pollán M.

Environ Health Perspect. 2016 Oct;124(10):1575-1582. Epub 2016 May 20.

15.

AI-related BMD variation in actual practice conditions: A prospective cohort study.

Rodríguez-Sanz M, Prieto-Alhambra D, Servitja S, Garcia-Giralt N, Garrigos L, Rodriguez-Morera J, Albanell J, Martínez-García M, González I, Diez-Perez A, Tusquets I, Nogués X.

Endocr Relat Cancer. 2016 Apr;23(4):303-12. doi: 10.1530/ERC-16-0025. Epub 2016 Feb 24.

PMID:
26911377
16.

Perinatal and childhood factors and risk of breast cancer subtypes in adulthood.

Lope V, García-Esquinas E, Pérez-Gómez B, Altzibar JM, Gracia-Lavedan E, Ederra M, Molina de la Torre AJ, LLorca FJ, Tardón A, Moreno V, Bayo J, Salas-Trejo D, Marcos-Gragera R, Pumarega J, Dierssen-Sotos T, Lera JP, de Miguel Medina MA, Tusquets I, Amiano P, Boldo E, Kogevinas M, Aragonés N, Castaño-Vinyals G, Pollán M.

Cancer Epidemiol. 2016 Feb;40:22-30. doi: 10.1016/j.canep.2015.11.004. Epub 2015 Nov 21.

17.

Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance.

Servitja S, Martos T, Rodriguez Sanz M, Garcia-Giralt N, Prieto-Alhambra D, Garrigos L, Nogues X, Tusquets I.

Ther Adv Med Oncol. 2015 Sep;7(5):291-6. doi: 10.1177/1758834015598536. Review.

18.

Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.

González-Martín A, Alba E, Ciruelos E, Cortés J, Llombart A, Lluch A, Andrés R, Álvarez I, Aramendía JM, de la Peña FA, Barnadas A, Batista N, Calvo L, Galve E, García-Palomo A, García-Sáenz JÁ, de la Haba J, López R, López-Vivanco G, Martínez-Jáñez N, de Dueñas EM, Plazaola A, Rodríguez-Lescure Á, Ruiz M, Sánchez-Rovira P, Santaballa A, Seguí MÁ, Tusquets I, Zamora P, Martín M.

Curr Cancer Drug Targets. 2016;16(5):415-28. Review.

PMID:
26278712
19.

CYP11A1 expression in bone is associated with aromatase inhibitor-related bone loss.

Rodríguez-Sanz M, García-Giralt N, Prieto-Alhambra D, Servitja S, Balcells S, Pecorelli R, Díez-Pérez A, Grinberg D, Tusquets I, Nogués X.

J Mol Endocrinol. 2015 Aug;55(1):69-79. doi: 10.1530/JME-15-0079. Epub 2015 Jun 24.

PMID:
26108486
20.

Potential clinical relevant drug-drug interactions: comparison between different compendia, do we have a validated method?

Conde-Estévez D, Echeverría-Esnal D, Tusquets I, Albanell J.

Ann Oncol. 2015 Jun;26(6):1272. doi: 10.1093/annonc/mdv151. Epub 2015 Mar 19. No abstract available.

PMID:
25791633
21.

Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.

García-Parra J, Dalmases A, Morancho B, Arpí O, Menendez S, Sabbaghi M, Zazo S, Chamizo C, Madoz J, Eroles P, Servitja S, Tusquets I, Yelamos J, Lluch A, Arribas J, Rojo F, Rovira A, Albanell J.

Eur J Cancer. 2014 Oct;50(15):2725-34. doi: 10.1016/j.ejca.2014.07.004. Epub 2014 Aug 12.

PMID:
25128455
22.

Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study (ZOMAR study).

Barnadas A, Manso L, de la Piedra C, Meseguer C, Crespo C, Gómez P, Calvo L, Martinez P, Ruiz-Borrego M, Perelló A, Antón A, Codes M, Margelí M, Murias A, Salvador J, Seguí MÁ, de Juan A, Gavilá J, Luque M, Pérez D, Zamora P, Arizcuma A, Chacón JI, Heras L, Martin-Fernández M, Mahillo-Fernández I, Tusquets I.

Bone. 2014 Nov;68:32-40. doi: 10.1016/j.bone.2014.07.036. Epub 2014 Aug 7.

PMID:
25108081
23.

An overview of randomized clinical trials in metastatic breast cancer: variables affecting regulatory drug approval.

Conde-Estévez D, Tusquets I, Servitja S, Martínez-García M, Salas E, Albanell J.

Anticancer Drugs. 2014 Oct;25(9):992-7. doi: 10.1097/CAD.0000000000000130. Review.

PMID:
24892723
24.

Gene expression profiling in true interval breast cancer reveals overactivation of the mTOR signaling pathway.

Rojo F, Domingo L, Sala M, Zazo S, Chamizo C, Menendez S, Arpi O, Corominas JM, Bragado R, Servitja S, Tusquets I, Nonell L, Macià F, Martínez J, Rovira A, Albanell J, Castells X.

Cancer Epidemiol Biomarkers Prev. 2014 Feb;23(2):288-99. doi: 10.1158/1055-9965.EPI-13-0761. Epub 2013 Dec 17.

25.

Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-кB target genes in human breast cancer.

Dalmases A, González I, Menendez S, Arpí O, Corominas JM, Servitja S, Tusquets I, Chamizo C, Rincón R, Espinosa L, Bigas A, Eroles P, Furriol J, Lluch A, Rovira A, Albanell J, Rojo F.

Oncotarget. 2014 Jan 15;5(1):196-210.

26.

Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.

Lluch A, Alvarez I, Muñoz M, Seguí MÁ, Tusquets I, García-Estévez L.

Crit Rev Oncol Hematol. 2014 Jan;89(1):62-72. doi: 10.1016/j.critrevonc.2013.08.001. Epub 2013 Aug 21. Review.

PMID:
24071503
27.

SEOM clinical guidelines for the systemic treatment of early breast cancer 2013.

Del Barco S, Ciruelos E, Tusquets I, Ruiz M, Barnadas A; SEOM.

Clin Transl Oncol. 2013 Dec;15(12):1011-7. doi: 10.1007/s12094-013-1084-3. Epub 2013 Aug 27. Review.

PMID:
23979909
28.

Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study.

Garcia-Giralt N, Rodríguez-Sanz M, Prieto-Alhambra D, Servitja S, Torres-Del Pliego E, Balcells S, Albanell J, Grinberg D, Diez-Perez A, Tusquets I, Nogués X.

Breast Cancer Res Treat. 2013 Jul;140(2):385-95. doi: 10.1007/s10549-013-2638-3. Epub 2013 Jul 19.

PMID:
23868189
29.

Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain.

Font R, Espinas JA, Gil-Gil M, Barnadas A, Ojeda B, Tusquets I, Segui MA, Margelí M, Arcusa A, Prat A, Garcia M, Borras JM.

Br J Cancer. 2012 Oct 9;107(8):1249-56. doi: 10.1038/bjc.2012.389. Epub 2012 Sep 6.

30.

Factors affecting 5- and 10-year survival of women with breast cancer: an analysis based on a public general hospital in Barcelona.

Macià F, Porta M, Murta-Nascimento C, Servitja S, Guxens M, Burón A, Tusquets I, Albanell J, Castells X.

Cancer Epidemiol. 2012 Dec;36(6):554-9. doi: 10.1016/j.canep.2012.07.003. Epub 2012 Jul 31.

PMID:
22854422
31.

Finding the right dose of fulvestrant in breast cancer.

Estévez L, Alvarez I, Tusquets I, Seguí MA, Muñoz M, Fernández Y, Lluch A.

Cancer Treat Rev. 2013 Apr;39(2):136-41. doi: 10.1016/j.ctrv.2012.06.003. Epub 2012 Jul 15. Review.

PMID:
22795960
32.

Are ER+PR+ and ER+PR- breast tumors genetically different? A CGH array study.

Carracedo A, Salido M, Corominas JM, Rojo F, Ferreira BI, Suela J, Tusquets I, Corzo C, Segura M, Espinet B, Cigudosa JC, Arumi M, Albanell J, Serrano S, Solé F.

Cancer Genet. 2012 Apr;205(4):138-46. doi: 10.1016/j.cancergen.2012.01.001.

PMID:
22559974
33.

Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study.

Prieto-Alhambra D, Servitja S, Javaid MK, Garrigós L, Arden NK, Cooper C, Albanell J, Tusquets I, Diez-Perez A, Nogues X.

Breast Cancer Res Treat. 2012 Jun;133(3):1159-67. doi: 10.1007/s10549-012-2013-9. Epub 2012 Mar 21.

PMID:
22434523
34.

Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2.

Servitja S, Ramos M, Gil M, Sánchez-Rovira P, Vázquez-Estevez S, Virizuela JA, García-Estevez L, Velasco A, Tusquets I.

Anticancer Drugs. 2012 Feb;23(2):239-46. doi: 10.1097/CAD.0b013e32834e2fe4.

PMID:
22112931
35.

Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer.

Servitja S, Nogués X, Prieto-Alhambra D, Martínez-García M, Garrigós L, Peña MJ, de Ramon M, Díez-Pérez A, Albanell J, Tusquets I.

Breast. 2012 Feb;21(1):95-101. doi: 10.1016/j.breast.2011.09.001. Epub 2011 Sep 15.

PMID:
21924904
36.

Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer.

Rojo F, García-Parra J, Zazo S, Tusquets I, Ferrer-Lozano J, Menendez S, Eroles P, Chamizo C, Servitja S, Ramírez-Merino N, Lobo F, Bellosillo B, Corominas JM, Yelamos J, Serrano S, Lluch A, Rovira A, Albanell J.

Ann Oncol. 2012 May;23(5):1156-64. doi: 10.1093/annonc/mdr361. Epub 2011 Sep 9.

PMID:
21908496
37.

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.

Albanell J, González A, Ruiz-Borrego M, Alba E, García-Saenz JA, Corominas JM, Burgues O, Furio V, Rojo A, Palacios J, Bermejo B, Martínez-García M, Limon ML, Muñoz AS, Martín M, Tusquets I, Rojo F, Colomer R, Faull I, Lluch A.

Ann Oncol. 2012 Mar;23(3):625-31. doi: 10.1093/annonc/mdr278. Epub 2011 Jun 6.

PMID:
21652577
38.

Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer.

Guerrero A, Servitja S, Rodríguez-Lescure A, Calvo L, del Barco S, Quintanar MT, Juárez JI, Gayo J, Llombart A, Tusquets I.

Anticancer Drugs. 2011 Mar;22(3):283-9. doi: 10.1097/CAD.0b013e3283425c55.

PMID:
21150776
39.

Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study.

Prieto-Alhambra D, Javaid MK, Servitja S, Arden NK, Martinez-García M, Diez-Perez A, Albanell J, Tusquets I, Nogues X.

Breast Cancer Res Treat. 2011 Feb;125(3):869-78. doi: 10.1007/s10549-010-1075-9. Epub 2010 Jul 28.

PMID:
20665105
40.

Current controversies in the management of breast cancer.

Tusquets I, García-Estévez L, Adrover E, Calvo L, Alvarez I, García Mata J, Fernández Y, Margueli M, Seguí MA, Muñoz M, Rodríguez C, Rodríguez Lescure A, Colomer R, Gascón P, Martín M, Alba E, Barnadas A, Llombart A, Albanell J, Lluch A.

Clin Transl Oncol. 2010 Apr;12(4):278-86. Review. Erratum in: Clin Transl Oncol. 2010 Aug;12(8):581. Muñoz, M [added].

PMID:
20462837
41.

Current perspectives of treatment of ductal carcinoma in situ.

Estévez LG, Alvarez I, Seguí MÁ, Muñoz M, Margelí M, Miró C, Rubio C, Lluch A, Tusquets I.

Cancer Treat Rev. 2010 Nov;36(7):507-17. doi: 10.1016/j.ctrv.2010.03.007. Epub 2010 May 11. Review.

PMID:
20462701
42.

Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.

Nogues X, Servitja S, Peña MJ, Prieto-Alhambra D, Nadal R, Mellibovsky L, Albanell J, Diez-Perez A, Tusquets I.

Maturitas. 2010 Jul;66(3):291-7. doi: 10.1016/j.maturitas.2010.03.012. Epub 2010 Apr 15.

PMID:
20399042
43.

Supportive care for patients with early breast cancer.

García-Estévez L, Tusquets I, Alvarez I, Rodríguez C, Fernández Y, Seguí MA, García-Mata J, Lluch A.

Clin Transl Oncol. 2010 Jan;12(1):32-42. doi: 10.1007/s12094-010-0464-1. Review.

PMID:
20080469
44.

FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors.

Carracedo A, Egervari K, Salido M, Rojo F, Corominas JM, Arumi M, Corzo C, Tusquets I, Espinet B, Rovira A, Albanell J, Szollosi Z, Serrano S, Solé F.

Breast Cancer Res. 2009;11(2):402. doi: 10.1186/bcr2239. Epub 2009 Apr 21. No abstract available.

45.

Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin.

Rojo F, González-Navarrete I, Bragado R, Dalmases A, Menéndez S, Cortes-Sempere M, Suárez C, Oliva C, Servitja S, Rodriguez-Fanjul V, Sánchez-Pérez I, Campas C, Corominas JM, Tusquets I, Bellosillo B, Serrano S, Perona R, Rovira A, Albanell J.

Clin Cancer Res. 2009 May 15;15(10):3530-9. doi: 10.1158/1078-0432.CCR-08-2070. Epub 2009 May 5.

46.

Epidemiologic study to assess patient involvement in choice of adjuvant chemotherapy for breast cancer (PROSA Study).

Tusquets I, Espinosa Arranz E, Méndez M, Gil JM, Guallar JL, Perulero N; PROSA Study investigators.

Clin Transl Oncol. 2009 Apr;11(4):221-7.

PMID:
19380299
47.

Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial.

Barnadas A, Gil M, González S, Tusquets I, Muñoz M, Arcusa A, Prieto L, Margelí-Vila M, Moreno A.

Br J Cancer. 2009 Feb 10;100(3):442-9. doi: 10.1038/sj.bjc.6604868. Epub 2009 Jan 20.

48.

Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial.

Del Barco S, Colomer R, Calvo L, Tusquets I, Adrover E, Sánchez P, Rifà J, De la Haba J, Virizuela JA.

Breast Cancer Res Treat. 2009 Jul;116(2):351-8. doi: 10.1007/s10549-008-0218-8. Epub 2008 Oct 22.

PMID:
18941891
49.

Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer.

Muñoz M, Estévez LG, Alvarez I, Fernández Y, Margelí M, Tusquets I, Seguí MA, Lluch A.

Cancer Treat Rev. 2008 Dec;34(8):701-9. doi: 10.1016/j.ctrv.2008.04.002. Epub 2008 Oct 14. Review.

PMID:
18922644
50.

A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma.

Colomer R, Monzo M, Tusquets I, Rifa J, Baena JM, Barnadas A, Calvo L, Carabantes F, Crespo C, Muñoz M, Llombart A, Plazaola A, Artells R, Gilabert M, Lloveras B, Alba E.

Clin Cancer Res. 2008 Feb 1;14(3):811-6. doi: 10.1158/1078-0432.CCR-07-1923.

Supplemental Content

Loading ...
Support Center